Full Press Release Details
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) --MiNKTherapeutics,Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 17, 2026, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET.
To participate in the Annual Shareholders Meeting, shareholders should visitwww.virtualshareholdermeeting.com/INKT2026and enter the 16-digit control number found in their proxy materials. Guests may also access the meeting in listen-only mode. No control number is required for guests.
Webcast Information:
Date: Wednesday, June 17, 2026
Time: 9:30 a.m. ET
A live webcast and replay will be accessible from the Company's website athttps://investor.minktherapeutics.com/events-and-presentationsand atwww.virtualshareholdermeeting.com/INKT2026.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf allogeneic iNKT cell therapies for life-threatening conditions driven by immune dysfunction. The company's lead program, agenT-797, is being evaluated in acute lung injury and critical illness, with a pipeline that extends across immuno-oncology, transplant medicine, and other settings where dysregulated immunity is a driver of morbidity and mortality. MiNK believes that iNKT cell biology, because of its regulatory role across innate and adaptive immunity, may represent a foundational approach to immune restoration applicable across a broad range of conditions. For more information, visitwww.minktherapeutics.com.